Quarterly report pursuant to Section 13 or 15(d)

NOTES PAYABLE (Details 1)

v3.22.1
NOTES PAYABLE (Details 1)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2022
USD ($)
Equity_Instrument
$ / shares
Dec. 31, 2021
USD ($)
Equity_Instrument
$ / shares
Debt Instrument [Line Items]    
Principal Outstanding $ 24,262 $ 22,339
Unamortized Discount 3,921 4,332
Carrying Amount $ 20,341 $ 18,007
Underlying Shares Notes | Equity_Instrument 10,126,654 10,173,099
Convertible notes payable, Current $ 10,569 $ 10,158
2021 Convertible Notes Payable [Member]    
Debt Instrument [Line Items]    
Interest rate 2.00% 2.00%
Term of Notes 3 years 3 years
Conversion Price | $ / shares [1] $ 1.48 $ 1.48
Principal Outstanding $ 14,490 $ 14,490
Unamortized Discount 3,921 4,332
Carrying Amount $ 10,569 $ 10,158
Underlying Shares Notes | Equity_Instrument 9,806,850 9,856,343
Convertible Notes Payable [Member]    
Debt Instrument [Line Items]    
Principal Outstanding $ 17,640 $ 17,640
Unamortized Discount 3,921 4,332
Carrying Amount $ 13,719 $ 13,308
Underlying Shares Notes | Equity_Instrument 10,126,654 10,173,099
Principal Outstanding, Current $ 14,490 $ 14,490
Unamortized Discount, Current 3,921 4,332
Convertible notes payable, Current $ 10,569 $ 10,158
Underlying Shares Notes, Current | Equity_Instrument 9,806,850 9,856,343
Principal Outstanding, Non Current $ 3,150 $ 3,150
Notes payable, non-current $ 3,150 $ 3,150
Underlying Shares Notes, Non Current | Equity_Instrument 319,804 316,756
2020 Convertible Notes Payable [Member]    
Debt Instrument [Line Items]    
Interest rate 12.00% 12.00%
Term of Notes 3 years 3 years
Conversion Price | $ / shares [2] $ 10.00 $ 10.00
Principal Outstanding $ 3,150 $ 3,150
Carrying Amount $ 3,150 $ 3,150
Underlying Shares Notes | Equity_Instrument 319,804 316,756
[1]

The notes are convertible into Emmaus Life Sciences, Inc. shares. Beginning February 28, 2022, the note holders became entitled to call for early redemption of the convertible notes payable, because the Company common stock was not approved for listing on the NYSE American, the Nasdaq Capital Market or other Trading Market (as defined in the agreement). Accordingly, the notes were classified as current.
[2] This note is convertible into shares of EMI Holding, Inc., a wholly owned subsidiary of Emmaus.